U.S. Influenza Diagnostics Market Share To Reach Scalable Heights Of Growth

U.S. Influenza Diagnostics Market Summary

The U.S. influenza diagnostics market size was valued at USD 179.9 million in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030. Recurring seasonal outbreaks of influenza remain the primary driver of the market, creating a consistent need for effective testing solutions. Increasing awareness among the population, widespread screening programs, and rapid advancements in diagnostic technologies are significantly contributing to market expansion. Influenza, being a highly contagious viral infection, spreads quickly in public places where infected individuals act as carriers, thereby fueling the demand for reliable diagnostic methods on a large scale.

The growing prevalence of influenza cases in the U.S. is further accelerating market growth. According to the Centers for Disease Control and Prevention (CDC), the 2021-2022 influenza season caused around 9 million illnesses, 4 million medical visits, 10,000 hospitalizations, and 5,000 fatalities. The flu season occurred in two waves, with the second wave leading to a higher number of hospitalizations, which underscored the urgent need for timely and accurate diagnostic testing.

Key Market Trends & Insights

• The rapid influenza diagnostic tests (RIDT) segment accounted for the largest revenue share of 36.2% in 2022 and is projected to expand at the fastest CAGR of 6.5% from 2023 to 2030. The popularity of RIDTs can be attributed to their widespread availability, ease of use, and ability to deliver fast results, making them a preferred choice for quick and efficient diagnosis. These factors make RIDTs a vital part of the U.S. influenza diagnostics market landscape.
• The hospitals segment dominated the market with a 40.4% revenue share in 2022, largely due to the rising prevalence of influenza and the increasing number of patients seeking medical care. According to CDC data, during the 2021-2022 influenza season, the estimated symptomatic illness burden ranged from 7.6 to 15.5 million cases, many of which required hospital-based diagnostic support. Hospitals continue to be primary centers for influenza testing, owing to their capacity to manage high patient volumes and their reliance on both rapid and advanced diagnostic tools.
• By end-use, the market is segmented into hospitals, laboratories, and point-of-care testing (POCT). The POCT segment is expected to grow at the fastest CAGR of 6.3% during the forecast period, supported by continuous technological innovations and improved test accuracy. POCT devices are gaining importance due to their portability, convenience, and rapid turnaround time, which make them especially effective in outpatient settings and community healthcare.
• Laboratory testing also remains a significant component of the market, primarily using real-time PCR techniques for confirmatory diagnosis. At the same time, the growing popularity of home testing kits has created substantial demand for influenza diagnostics in recent years. These kits offer consumers a convenient and reliable option, reducing the dependency on clinical visits while driving market competition. The increased demand has created opportunities for new entrants to introduce advanced and disruptive technologies, thereby fostering innovation in the U.S. influenza diagnostics sector.

Order a free sample PDF of the U.S. Influenza Diagnostics Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2022 Market Size: USD 179.9 million
• 2030 Projected Market Size: USD 282.9 million
• CAGR (2023- 2030): 5.9%

Key Companies & Market Share Insights

Several product launches are further fueling market growth. For instance, in October 2017, Alere Inc. received 510(k) marketing clearance from the U.S. FDA for its Alere i Influenza A & B 2 diagnostic test. This rapid molecular assay provides highly accurate results in both adults and children within a short period, enhancing the speed and reliability of influenza detection. Similarly, in August 2017, Meridian Bioscience expanded its ImmunoCard STAT! product line with the launch of ImmunoCard STAT! FLU A&B, capable of detecting influenza A and B in nasal swabs within 10-15 minutes. Such frequent product introductions highlight the competitive nature of the market and the ongoing efforts by key players to strengthen their portfolios.

Key Players

• 3M
• Abbott
• BD
• Meridian Bioscience
• Quidel Corporation
• F. Hoffmann-La Roche Ltd
• SA Scientific Ltd.
• SEKISUI Diagnostics
• Thermo Fisher Scientific Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The U.S. influenza diagnostics market is poised for steady growth, supported by recurring seasonal outbreaks, increasing disease awareness, and rapid technological advancements in diagnostic tools. Segments such as RIDTs and POCT are expected to experience the fastest adoption due to their speed, accuracy, and user-friendly design. The rising burden of influenza cases continues to drive demand across hospitals, laboratories, and home-based testing kits, creating opportunities for innovation and new market entrants. With consistent product launches, expanding diagnostic technologies, and supportive healthcare infrastructure, the market is expected to remain highly dynamic, playing a crucial role in controlling seasonal influenza outbreaks.